Cargando…
Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA
mRNA based therapies hold great promise for the treatment of genetic diseases. However, this therapeutic approach suffers from multiple challenges including the short half-life of exogenously administered mRNA and subsequent protein production. Modulation of untranslated regions (UTR) represents one...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152433/ https://www.ncbi.nlm.nih.gov/pubmed/29578372 http://dx.doi.org/10.1080/15476286.2018.1450054 |
_version_ | 1783357366256795648 |
---|---|
author | Asrani, Kirtika H. Farelli, Jeremiah D. Stahley, Mary R. Miller, Rebecca L. Cheng, Christopher J. Subramanian, Romesh R. Brown, Jeffrey M. |
author_facet | Asrani, Kirtika H. Farelli, Jeremiah D. Stahley, Mary R. Miller, Rebecca L. Cheng, Christopher J. Subramanian, Romesh R. Brown, Jeffrey M. |
author_sort | Asrani, Kirtika H. |
collection | PubMed |
description | mRNA based therapies hold great promise for the treatment of genetic diseases. However, this therapeutic approach suffers from multiple challenges including the short half-life of exogenously administered mRNA and subsequent protein production. Modulation of untranslated regions (UTR) represents one approach to enhance both mRNA stability and translation efficiency. The current studies describe and validate screening methods using a diverse set of 5′UTR and 3′UTR combinations for improved expression of the Arginase 1 (ARG1) protein, a potential therapeutic mRNA target. Data revealed a number of critical aspects which need to be considered when developing a screening approach for engineering mRNA improvements. First, plasmid-based screening methods do not correlate with protein expression driven by exogenously expressed mRNA. Second, improved ARG1 protein production was driven by increased translation and not improved mRNA stability. Finally, the 5′ UTR appears to be the key driver in protein expression for exogenously delivered mRNA. From the testing of the combinatorial library, the 5′UTR for complement factor 3 (C3) and cytochrome p4502E1 (CYP2E1) showed the largest and most consistent increase in protein expression relative to a reference UTR. Collectively, these data provide important information for the development and optimization of therapeutic mRNAs. |
format | Online Article Text |
id | pubmed-6152433 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-61524332018-09-26 Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA Asrani, Kirtika H. Farelli, Jeremiah D. Stahley, Mary R. Miller, Rebecca L. Cheng, Christopher J. Subramanian, Romesh R. Brown, Jeffrey M. RNA Biol Research Paper mRNA based therapies hold great promise for the treatment of genetic diseases. However, this therapeutic approach suffers from multiple challenges including the short half-life of exogenously administered mRNA and subsequent protein production. Modulation of untranslated regions (UTR) represents one approach to enhance both mRNA stability and translation efficiency. The current studies describe and validate screening methods using a diverse set of 5′UTR and 3′UTR combinations for improved expression of the Arginase 1 (ARG1) protein, a potential therapeutic mRNA target. Data revealed a number of critical aspects which need to be considered when developing a screening approach for engineering mRNA improvements. First, plasmid-based screening methods do not correlate with protein expression driven by exogenously expressed mRNA. Second, improved ARG1 protein production was driven by increased translation and not improved mRNA stability. Finally, the 5′ UTR appears to be the key driver in protein expression for exogenously delivered mRNA. From the testing of the combinatorial library, the 5′UTR for complement factor 3 (C3) and cytochrome p4502E1 (CYP2E1) showed the largest and most consistent increase in protein expression relative to a reference UTR. Collectively, these data provide important information for the development and optimization of therapeutic mRNAs. Taylor & Francis 2018-03-26 /pmc/articles/PMC6152433/ /pubmed/29578372 http://dx.doi.org/10.1080/15476286.2018.1450054 Text en © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
spellingShingle | Research Paper Asrani, Kirtika H. Farelli, Jeremiah D. Stahley, Mary R. Miller, Rebecca L. Cheng, Christopher J. Subramanian, Romesh R. Brown, Jeffrey M. Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA |
title | Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA |
title_full | Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA |
title_fullStr | Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA |
title_full_unstemmed | Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA |
title_short | Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA |
title_sort | optimization of mrna untranslated regions for improved expression of therapeutic mrna |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152433/ https://www.ncbi.nlm.nih.gov/pubmed/29578372 http://dx.doi.org/10.1080/15476286.2018.1450054 |
work_keys_str_mv | AT asranikirtikah optimizationofmrnauntranslatedregionsforimprovedexpressionoftherapeuticmrna AT farellijeremiahd optimizationofmrnauntranslatedregionsforimprovedexpressionoftherapeuticmrna AT stahleymaryr optimizationofmrnauntranslatedregionsforimprovedexpressionoftherapeuticmrna AT millerrebeccal optimizationofmrnauntranslatedregionsforimprovedexpressionoftherapeuticmrna AT chengchristopherj optimizationofmrnauntranslatedregionsforimprovedexpressionoftherapeuticmrna AT subramanianromeshr optimizationofmrnauntranslatedregionsforimprovedexpressionoftherapeuticmrna AT brownjeffreym optimizationofmrnauntranslatedregionsforimprovedexpressionoftherapeuticmrna |